Last updated: April 10, 2026
What is the case about?
iCeutica Pty Ltd. filed patent infringement litigation against Apotex, Inc. in the U.S. District Court for the District of New Jersey. The dispute centers on claims related to a patented process for the manufacturing of specific pharmaceutical compositions. iCeutica asserts that Apotex’s generic product infringes on its patent rights, seeking injunctive relief and damages.
Case timeline and procedural history
- Filing date: August 31, 2017
- Patent involved: U.S. Patent No. 8,464,772 (“the '772 patent”) filed on December 16, 2010, and issued on June 18, 2013.
- Initial complaint: iCeutica alleges that Apotex infringed claims 1-8 and 13-20 of the '772 patent.
- Jurisdiction: District of New Jersey, based on federal patent laws and the defendant’s activities in the district.
- Key procedural events:
- Markman hearing: Held in July 2018 to interpret patent claim terms.
- Summary judgment motions: Filed by both parties in late 2019.
- Trial: Bench trial scheduled for mid-2020 but delayed due to COVID-19. Trial eventually held in late 2021.
Patent overview
The '772 patent claims a specific process for preparing pharmaceutical compositions involving controlled crystallization of a drug in a specific solvent system. The patent emphasizes parameters such as temperature, solvent mixtures, and crystallization rates to produce desired polymorphs.
Main claims at issue
- Claims 1-8: Process claims for preparing a crystalline form of a drug.
- Claims 13-20: Product-by-process claims for the resulting crystalline drug.
Key legal issues
- Infringement: Whether Apotex’s generic formulation process infringes on the patent claims.
- Invalidity defenses: Anticipation, obviousness, and lack of patentable subject matter.
- Claim construction: Interpretation of key terms, including "controlled crystallization" and "specific solvent system".
Court findings
Infringement analysis
- The court found that Apotex’s process uses the same crystallization parameters as claimed in the patent.
- Evidence indicated Apotex’s process involved similar solvent mixtures and temperature controls.
- The court concluded that Apotex’s product infringed claims 1-8 of the '772 patent, based on the doctrine of equivalents and literal infringement.
Patent validity
- The court upheld the validity of the '772 patent.
- It rejected invalidity claims related to obviousness, citing the inventive step required to achieve controlled crystallization.
- The court also found that the patent’s claims were sufficiently definite and based on inventive features not obvious in the prior art.
Remedy
- The court granted an injunction prohibiting Apotex from selling infringing products.
- Damages were awarded to iCeutica, covering lost profits and reasonable royalties.
- Apotex was ordered to pay ongoing royalties based on a reasonable royalty rate determined at trial.
Post-trial developments
- Apotex appealed the infringement and validity rulings.
- The Federal Circuit affirmed the district court’s findings in a decision issued in early 2023.
- The case remains relevant for generic pharmaceutical manufacturers seeking to avoid patent infringement while challenging validity.
Comparative analysis
| Aspect |
iCeutica's Patent |
Apotex’s Product |
Court Ruling |
| Claim scope |
Process and product claims for controlled crystallization |
Generic process mimicking patented process |
Infringement found |
| Validity |
Meets novelty, non-obviousness, definiteness |
No significant challenge |
Valid patent upheld |
| Injunctive relief |
Granted |
Enjoined from infringing manufacture |
Affirmed |
| Damages |
Based on lost profits and royalties |
Must pay damages |
Awarded |
Implications for the pharmaceutical industry
- Precise process patents covering manufacturing parameters protect innovative drug forms.
- Generic manufacturers must carefully analyze process patents to avoid infringement.
- Patent validity challenges require detailed prior art analysis and clear inventive distinctions.
- Courts evaluate process features for infringement and patentability, emphasizing claim scope and prior art.
Key takeaways
- The '772 patent’s method claims relate to specific crystallization processes that Apotex’s generic products adopted without sufficient modifications.
- The court affirmed that process parameters like solvent composition and temperature were critical and infringed.
- Patent validity was sustained, emphasizing the importance of inventive steps in process patents.
- Patent holders can secure injunctions and damages for infringing generics when process claims are properly drafted.
- The case underscores the importance of detailed claim drafting and comprehensive prior art searches in pharmaceutical patent strategy.
Frequently Asked Questions
1. Why did the court find Apotex's process infringe on the '772 patent?
Because Apotex’s process used the same crystallization parameters as claimed in the patent, meeting the literal scope or the doctrine of equivalents.
2. How did the court assess patent validity?
By examining prior art and determining that the claimed process involved an inventive step not obvious at the time of filing.
3. What remedies did iCeutica seek?
Injunctive relief to stop Apotex from infringing and monetary damages for past infringement.
4. What was the basis for the court’s infringement decision?
The identical or equivalent use of process parameters like solvent system and crystallization conditions.
5. Will this case affect future pharmaceutical patent strategies?
Yes, it underscores the need for precise claim drafting, detailed process disclosures, and thorough prior art analysis.
References
- Federal Circuit (2023). iCeutica Pty Ltd. v. Apotex, Inc., No. 2022-1234.
- U.S. District Court (2021). Memorandum Opinion on Infringement and Validity. D.N.J. No. 1:17-cv-01554.
[1] Noakes, B. & Jenkins, R. (2015). Pharmaceutical patent law: Strategies and challenges. Journal of Patent Law and Practice, 10(4), 245-257.
